11. Chen JJ, Silver D, Cantor S, Livingston DM, Scully R. 1999. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res 59(7 Suppl):1752s-1756s.

12. Christiansen CL, Wang F, Barton MB, Kreuter W, Elmore JG, Gelfand AE, Fletcher SW. 2000. Predicting the cumulative risk of false-positive mammograms. J Natl Cancer Inst 92(20):1657-1666.

13. Cutuli B, Cohen-Solal-Le Nir C, De Lafontan B, Mignotte H, Fichet V, Fay R, Servent V, Giard S, Charra-Brunaud C, Auvray H, Penault-Llorca F, Charpentier JC. 2001. Ductal carcinoma in situ of the breast results of conservative and radical treatments in 716 patients. Eur J Cancer 37(18):2365-2372.

14. Davey C, White V, Ward JE. 2002. Insurance repercussions of mammographic screening: what do women think? Med Sci Monit 8(12):LE54-LE55.

15. Dixon JM. 2003. Hormone replacement therapy and the breast. Surg Oncol 12(4):251-263.

16. Drossaert CH, Boer H, Seydel ER. 2001. Does mammographic screening and a negative result affect attitudes towards future breast screening? J Med Screen 8(4):204-212.

17. Drossaert CH, Boer H, Seydel ER. 2002. Monitoring women’s experiences during three rounds of breast cancer screening: results from a longitudinal study. J Med Screen 9(4):168-175.

18. Duffy SW, Tabar L, Chen HH, Holmqvist M, Yen MF, Abdsalah S, Epstein B, Frodis E, Ljungberg E, Hedborg-Melander C, Sundbom A, Tholin M, Wiege M, Akerlund A, Wu HM, Tung TS, Chiu YH, Chiu CP, Huang CC, Smith RA, Rosen M, Stenbeck M, Holmberg L. 2002. The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer 95(3):458-469.

19. Duffy SW, Tabar L, Vitak B, Day NE, Smith RA, Chen HH, Yen MF. 2003. The relative contributions of screen-detected in situ and invasive breast carcinomas in reducing mortality from the disease. Eur J Cancer 39(12):1755-1760.

20. Dummin L. Pathology Seen in Breast Imaging: DCIS. Web Page. Available at: http://medrad.city.unisa.edu.au/Breast/DCIS.html.

21. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. 1998. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 338(16):1089-1096.

22. Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G, Yankaskas BC, Rosenberg R, Carney PA, Kerlikowske K, Taplin SH, Urban N, Geller BM. 2002. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 94(20):1546-1554.

23. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C. 1996. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 275(12):913-918.

24. Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R. 2000. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 160(7):953-958.

25. Eusebi V, Foschini MP, Cook MG, Berrino F, Azzopardi JG. 1989. Long-term follow-up of in situ carcinoma of the breast with special emphasis on clinging carcinoma. Semin Diagn Pathol 6(2):165-173.

26. Feig SA. 2000. Ductal carcinoma in situ. Implications for screening mammography. Radiol Clin North Am 38(4):653-668, vii.

27. Feig SA. 2002. Effect of service screening mammography on population mortality from breast carcinoma. Cancer 95(3):451-457.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement